Accurian (platform of radio-frequency ablation)

2019: Entry into the market

At the end of February, 2019 Medtronic issued the Accurian platform which carries out radio-frequency ablation of nervous tissues for treatment of chronic pain.

Chronic pain which lasts more than three-six months significantly reduces working capacity and finally quality of life. Radio-frequency ablation is minimum invasive procedure of anesthesia: the current made by radio waves heats small area of nervous tissue and stops transfer of painful impulses, thereby reducing painful feelings.

The platform for radio-frequency ablation of Accurian combines the best hardware and the quad-core processor with the advanced software for exact control of power of current and the reached temperature that improves efficiency and the long-term result of treatment. Besides, the Accurian platform provides independent circuit management and has expanded functions which guarantee the accuracy of holding a procedure.

Medtronic issued the platform of radio-frequency ablation Accurian for treatment of chronic pain

The Accurian platform can perform standard, pulse and expanded procedures using probes with internal cooling and is capable to control completely the volume of nervous tissue subjected to influence. To simplify visual control, a system traces probe provision and also uses reports on other procedures, comparing data retrieveds and selecting the most effective solutions.

The company stated that Accurian was developed taking into account the last technology achievements and is carefully tested. On representatives of Medtronic, the Accurian platform is intuitive and simple in use, allows to upgrade easily a system if necessary and to execute expanded transactions. The platform should be updated at receipt of new data from researchers, and developers guarantee long service life.^[1]

Notes